FDA OKs Retrophin’s Thiola for cystinuria

The FDA approves Retrophin’s (NASDAQ:RTRX) enteric coated Thiola EC (tiopronin) for the treatment of a rare inherited disorder called cystinuria (high levels of the amino acid cysteine in the urine) that leads to kidney stones.

Commercial launch will commence in July.

Shares are up 3% after hours.

https://seekingalpha.com/news/3474766-fda-oks-retrophins-thiola-cystinuria-shares-3-percent-hours